Nanobiotix S.A. announced organizational changes to align with strategic priorities post European market approval for Hensify® (NBTXR3). Recently appointed CMO Dr. Edwina Baskin-Bey will join the Executive Board. Ms. Anne-Juliette Hermant will be appointed CPO and will join the Executive Board as well. As mentioned in a previous, former CMO Dr. Elsa Borghi will leave the Executive Board to take on a new function leading innovation and drug discovery. CBO Dr. Bernd Muehlenweg will step down from the Executive Board and exit the company. Dr. Patrick Tricoli will remain CEO of Nanobiotix Corp, the company’s U.S. affiliate, while also taking on a new role as Global Head of Business Development. Mr. Brandon Owens will join Nanobiotix as its newly appointed VP of Strategic Marketing and Corporate Communications.